A vs. RPRX: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at A and RPRX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
A’s market capitalization of 34.48 billion USD is substantially larger than RPRX’s 20.45 billion USD, indicating a significant difference in their market valuations.
A’s beta of 1.23 points to significantly higher volatility compared to RPRX (beta: 0.47), suggesting A has greater potential for both gains and losses relative to market movements.
| Symbol | A | RPRX |
|---|---|---|
| Company Name | Agilent Technologies, Inc. | Royalty Pharma plc |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Diagnostics & Research | Biotechnology |
| CEO | Padraig McDonnell | Pablo Gerardo Legorreta |
| Price | 121.38 USD | 36.37 USD |
| Market Cap | 34.48 billion USD | 20.45 billion USD |
| Beta | 1.23 | 0.47 |
| Exchange | NYSE | NASDAQ |
| IPO Date | November 18, 1999 | June 16, 2020 |
| ADR | No | No |
Historical Performance
This chart compares the performance of A and RPRX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
A
19.46%
Medical - Diagnostics & Research Industry
- Max
- 57.35%
- Q3
- 18.17%
- Median
- 2.69%
- Q1
- -16.72%
- Min
- -48.78%
In the upper quartile for the Medical - Diagnostics & Research industry, A’s Return on Equity of 19.46% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
RPRX
16.19%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
In the upper quartile for the Biotechnology industry, RPRX’s Return on Equity of 16.19% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Return on Invested Capital
A
11.71%
Medical - Diagnostics & Research Industry
- Max
- 42.99%
- Q3
- 11.55%
- Median
- 3.02%
- Q1
- -11.49%
- Min
- -40.79%
In the upper quartile for the Medical - Diagnostics & Research industry, A’s Return on Invested Capital of 11.71% signifies a highly effective use of its capital to generate profits when compared to its peers.
RPRX
9.56%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
In the upper quartile for the Biotechnology industry, RPRX’s Return on Invested Capital of 9.56% signifies a highly effective use of its capital to generate profits when compared to its peers.
Net Profit Margin
A
17.59%
Medical - Diagnostics & Research Industry
- Max
- 22.76%
- Q3
- 15.19%
- Median
- 1.64%
- Q1
- -22.25%
- Min
- -78.24%
A Net Profit Margin of 17.59% places A in the upper quartile for the Medical - Diagnostics & Research industry, signifying strong profitability and more effective cost management than most of its peers.
RPRX
48.24%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
A Net Profit Margin of 48.24% places RPRX in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin
A
21.38%
Medical - Diagnostics & Research Industry
- Max
- 36.06%
- Q3
- 20.26%
- Median
- 6.15%
- Q1
- -21.89%
- Min
- -82.21%
An Operating Profit Margin of 21.38% places A in the upper quartile for the Medical - Diagnostics & Research industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
RPRX
83.95%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
An Operating Profit Margin of 83.95% places RPRX in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | A | RPRX |
|---|---|---|
| Return on Equity (TTM) | 19.46% | 16.19% |
| Return on Assets (TTM) | 9.59% | 6.20% |
| Return on Invested Capital (TTM) | 11.71% | 9.56% |
| Net Profit Margin (TTM) | 17.59% | 48.24% |
| Operating Profit Margin (TTM) | 21.38% | 83.95% |
| Gross Profit Margin (TTM) | 53.79% | 99.66% |
Financial Strength
Current Ratio
A
2.09
Medical - Diagnostics & Research Industry
- Max
- 6.91
- Q3
- 4.11
- Median
- 2.46
- Q1
- 1.44
- Min
- 0.73
A’s Current Ratio of 2.09 aligns with the median group of the Medical - Diagnostics & Research industry, indicating that its short-term liquidity is in line with its sector peers.
RPRX
1.56
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
RPRX’s Current Ratio of 1.56 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio
A
0.57
Medical - Diagnostics & Research Industry
- Max
- 1.10
- Q3
- 0.82
- Median
- 0.39
- Q1
- 0.21
- Min
- 0.01
A’s Debt-to-Equity Ratio of 0.57 is typical for the Medical - Diagnostics & Research industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
RPRX
1.14
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
With a Debt-to-Equity Ratio of 1.14, RPRX operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio
A
-472.33
Medical - Diagnostics & Research Industry
- Max
- 37.07
- Q3
- 5.62
- Median
- 1.76
- Q1
- -38.78
- Min
- -57.46
A has a negative Interest Coverage Ratio of -472.33. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
RPRX
7.70
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
RPRX’s Interest Coverage Ratio of 7.70 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | A | RPRX |
|---|---|---|
| Current Ratio (TTM) | 2.09 | 1.56 |
| Quick Ratio (TTM) | 1.60 | 1.56 |
| Debt-to-Equity Ratio (TTM) | 0.57 | 1.14 |
| Debt-to-Asset Ratio (TTM) | 0.29 | 0.43 |
| Net Debt-to-EBITDA Ratio (TTM) | 1.43 | 2.80 |
| Interest Coverage Ratio (TTM) | -472.33 | 7.70 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for A and RPRX. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
A
0.81%
Medical - Diagnostics & Research Industry
- Max
- 2.76%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 0.81%, A offers a more attractive income stream than most of its peers in the Medical - Diagnostics & Research industry, signaling a strong commitment to shareholder returns.
RPRX
2.36%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RPRX’s Dividend Yield of 2.36% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
Dividend Payout Ratio
A
23.76%
Medical - Diagnostics & Research Industry
- Max
- 37.46%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
A’s Dividend Payout Ratio of 23.76% is in the upper quartile for the Medical - Diagnostics & Research industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
RPRX
34.61%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 34.61%, RPRX’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
Dividend at a Glance
| Symbol | A | RPRX |
|---|---|---|
| Dividend Yield (TTM) | 0.81% | 2.36% |
| Dividend Payout Ratio (TTM) | 23.76% | 34.61% |
Valuation
Price-to-Earnings Ratio
A
29.67
Medical - Diagnostics & Research Industry
- Max
- 48.28
- Q3
- 44.64
- Median
- 29.13
- Q1
- 22.34
- Min
- 15.59
A’s P/E Ratio of 29.67 is within the middle range for the Medical - Diagnostics & Research industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
RPRX
14.43
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
RPRX’s P/E Ratio of 14.43 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Forward P/E to Growth Ratio
A
3.80
Medical - Diagnostics & Research Industry
- Max
- 4.18
- Q3
- 3.64
- Median
- 2.40
- Q1
- 0.57
- Min
- 0.04
A Forward PEG Ratio of 3.80 places A in the upper quartile for the Medical - Diagnostics & Research industry. This suggests the stock is potentially expensive compared to its peers relative to its growth forecast, which may warrant caution.
RPRX
0.81
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
RPRX’s Forward PEG Ratio of 0.81 is within the middle range of its peers in the Biotechnology industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
Price-to-Sales Ratio
A
5.20
Medical - Diagnostics & Research Industry
- Max
- 12.53
- Q3
- 6.19
- Median
- 3.58
- Q1
- 1.95
- Min
- 0.58
A’s P/S Ratio of 5.20 aligns with the market consensus for the Medical - Diagnostics & Research industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
RPRX
9.03
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
RPRX’s P/S Ratio of 9.03 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio
A
5.64
Medical - Diagnostics & Research Industry
- Max
- 10.67
- Q3
- 5.74
- Median
- 2.95
- Q1
- 1.30
- Min
- 0.39
The P/B Ratio is often not a primary valuation metric for the Medical - Diagnostics & Research industry.
RPRX
2.36
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
Valuation at a Glance
| Symbol | A | RPRX |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 29.67 | 14.43 |
| Forward PEG Ratio (TTM) | 3.80 | 0.81 |
| Price-to-Sales Ratio (P/S, TTM) | 5.20 | 9.03 |
| Price-to-Book Ratio (P/B, TTM) | 5.64 | 2.36 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 24.63 | 7.57 |
| EV-to-EBITDA (TTM) | 25.95 | 11.58 |
| EV-to-Sales (TTM) | 5.51 | 11.92 |